Pacemaker Electrode-Tissue Interface Patent Snapshot
The pacemaker electrode-tissue interface space is a concentrated, post-peak field dominated by a small cluster of established neuromodulation firms, with Boston Scientific Neuromodulation Corp holding the largest share among the top hundred filers. Annual filing volume peaked in 2021 and has eased since, signalling a maturing competitive dynamic rather than fresh accumulation.
Boston Scientific Neuromodulation leads a tightly held field
Boston Scientific Neuromodulation Corp tops the applicant ranking with 14 patent records, followed by Pacesetter Inc with 12 and Advanced Neuromodulation Systems Inc with 7, establishing a clear first tier among the ranked applicants visible in this query.
The top five filers — Boston Scientific Neuromodulation Corp, Pacesetter Inc, Advanced Neuromodulation Systems Inc, CVRX Inc, and Eagle Point Medical LLC — together account for 65% of the combined total of the ranked applicants visible in this query, reflecting a highly concentrated visible assignee structure with a pronounced gap to the second tier.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Boston Scientific Neuromodulation Corp | 14 | |
| 2 | Pacesetter Inc | 12 | |
| 3 | Advanced Neuromodulation Systems Inc | 7 | |
| 4 | CVRX Inc | 6 | |
| 5 | Eagle Point Medical LLC | 5 | |
| 6 | Telectronics | 5 | |
| 7 | Stimwave Technologies Inc | 3 | |
| 8 | NEURO & CARDIAC TECHNOLOGIES LLC | 3 | |
| 9 | BIOTRONIK SE & CO KG | 2 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 10 | Birinder R. Boveja | 2 | |
| 11 | Medtronic Inc | 2 | |
| 12 | Mizanur Rahman MD | 1 | |
| 13 | Duke University | 1 | |
| 14 | Reed A. Duthler | 1 | |
| 15 | Randy L. Brase | 1 | |
| 16 | Pacesetter Inc | 1 | |
| 17 | Jeffery V. Funderburk | 1 | |
| 18 | Robert R. Tong | 1 |
Such concentration suggests that IP positions in core electrotherapy techniques are well-defended by incumbent device makers, leaving limited room for undifferentiated entry without a clearly distinct technical approach.
Filing counts for 2024 and 2025 are likely under-represented due to standard patent-publication lag; the apparent near-zero activity in those years should not be read as cessation of R&D. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity peaked in 2021; electrotherapy dominates the technology mix
The annual filing trend and technology composition together reveal a field that built momentum through 2020–2021 and has since contracted, with patent activity concentrated almost entirely within a single IPC class.
Annual filing trend
Filings rose from 2 records in 2017 to a peak of 9 in 2021, then declined to 5 in 2022 and further in subsequent years. Figures for 2024 and 2025 are almost certainly understated due to publication lag and should not be interpreted as reflecting actual inventor activity.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy and radiation therapy) overwhelmingly is visible in the technology composition, with H03K (Pulse technique and logic circuits) and A61B (Diagnosis and surgery) each representing only a marginal share — indicating that the field’s IP has been framed almost exclusively through the therapeutic-stimulation lens rather than the signal-processing or diagnostic lens.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Porous pacemaker electrode tip
A porous cardiac pacemaker electrode comprising a concavo-convex electrode cap having a plurality of apertures therethrough and an electrode shaft having a supporting edge formed thereon to which the concave surface of the electrode cap is joined. The porous cardiac pacemaker electrode is produced by deforming a platinum plate into a concavo-convex shaped… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Method and system for providing therapy for autism… | 330 |
| 2 | Medical stimulator with multiple operational ampli… | 268 |
| 3 | Method and system for providing therapy for bulimi… | 230 |
| 4 | Method and system for altering regional cerebral b… | 227 |
| 5 | Method and system for providing therapy for bulimi… | 166 |
| 6 | Method and system for providing therapy for Alzhei… | 117 |
| 7 | Porous electrode for a pacemaker | 110 |
| 8 | Probe for cardiac pacemaker | 68 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
Boston Scientific Neuromodulation Corp
Holds the top position with 14 patent records, all concentrated in A61N 1 (Electrotherapy and radiation therapy). The portfolio is tightly focused on therapeutic stimulation with no observed diversification into adjacent signal-processing or diagnostic branches. Momentum data are not available for this applicant in the recent-versus-prior comparison.
patent records: 14Advanced Neuromodulation Systems Inc
Ranked third with 7 patent records and flagged as a new entrant in the recent filing period with 6 recent patent records, indicating a rapid acceleration from a low prior base. Uniquely among the top filers, Advanced Neuromodulation Systems holds coverage in both A61N 1 (electrotherapy, 7 records) and H03K 5 (pulse technique and logic circuits, 4 records), giving it the broadest cross-branch footprint in the landscape.
patent records: 7Frequently asked questions
The landscape covers 33 patent families in scope, providing a focused but meaningful view of IP activity specifically directed at the pacemaker electrode-tissue interface.
Boston Scientific Neuromodulation Corp leads with 14 patent records, followed by Pacesetter Inc with 12 and Advanced Neuromodulation Systems Inc with 7, based on the applicant ranking among the top hundred filers.
A61N (Electrotherapy and radiation therapy) is the overwhelmingly visible IPC class, with H03K (Pulse technique and logic circuits) and A61B (Diagnosis and surgery) each accounting for only a small fraction of patent records.
Annual filing activity peaked in 2021 with 9 patent records and has eased since, reaching 5 in 2022 and declining further in subsequent years. The lifecycle stage is classified as Decline. Figures for 2024 and 2025 are likely under-counted due to publication lag.
The United States is the primary jurisdiction with 38 patent records, followed by Europe (EPO) with 14, Australia with 7, and WIPO (PCT) with 5. The United Kingdom, Canada, and China each hold 1–2 records, indicating a strongly US-centric filing strategy among visible assignees.
No co-applicant or co-filing relationships are detected in this landscape’s collaboration data. The field appears to be characterised by proprietary, independently filed portfolios with no visible consortium or academic-industry partnership activity in the corpus.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.